Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF- α) inhibitors: a systematic review

Tumour necrosis factor- α (TNF-α) inhibitors are increasingly being used as immunomodulators to manage inflammatory conditions such as rheumatoid arthritis and Crohn’s disease. Reported serious side effects include an increased incidence of lymphoma and greater susceptibility to infections such as tuberculosis. The aim of this systematic review was to find out whether there is an associated risk of medication-related osteonecrosis of the jaw (MRONJ). Three authors independently searched PubMed, MEDLINE, EMBASE, CINAHL and the Cochrane Central Register of Controlled Trials for published reports of oral osteonecros is (ONJ) or osteomyelitis (OM) in patients who took anti TNF-α drugs and had no history of antiangiogenic agents or antiresorptive treatment.
Source: The British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Review Source Type: research